The formation and repair of cisplatin-DNA adducts in wild-type and cisplatin-resistant L1210 cells: Comparison of immunocytochemical determination with detection in isolated DNA

Chemico-Biological Interactions

Volumn 108, Issue 3, 1998, Pages 209-225

  Blommaert, Frank A ^a   Floot, Ben G J ^a   Van Dijk Knijnenburg, Helma C M ^b   Berends, Frits ^b   Baan, Robert A ^b   Schornagel, Jan H ^a   Den Engelse, Leo ^a   Fichtinger Schepman, Anne Marie J ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Cisplatin; DNA adducts; Drug resistance; Enzyme linked immunosorbent assay; Immunocytochemistry

Indexed keywords

ANTISERUM; CISPLATIN; DNA;

ANIMAL CELL; ARTICLE; COLONY FORMATION; DNA ADDUCT; DNA CONTENT; DNA DAMAGE; DNA SYNTHESIS; DRUG DNA BINDING; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH INHIBITION; IMMUNOCYTOCHEMISTRY; MOUSE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; BICARBONATES; CELL DIVISION; CISPLATIN; DNA ADDUCTS; DNA REPAIR; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; LEUKEMIA L1210; MICE; SENSITIVITY AND SPECIFICITY; THIOUREA;

ANIMALIA; RODENTIA;

EID: 0032579334     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(97)00108-7     Document Type: Article

References (37)

1. S.B. Howell (Ed), Platinum and Other Metal Co-ordination Compounds in Cancer Chemotherapy. Proceedings of the VIth Int. Symposium on Platinum and Other Metal Co-ordination Compounds in Cancer Chemotherapy, January 23-26, 1991, San Diego, California, Plenum Press, New York, 1991.
2. Reedijk J. The relevance of hydrogen binding in the mechanism of action of platinum antitumor compounds. Inorg. Chim. Acta. 198-200:1992;873-881.
3. Poirier M.C., Reed E., Zwelling L.A., Ozols R.F., Litterst C.L., Yuspa S.H. Polyclonal antibodies to quantitate cis-diamminedichloroplatinum(II)-DNA adducts in cancer patients and animal models. Environ. Health Perspect. 62:1985;89-94.
4. Reed E., Ozols R.F., Tarone R., Yuspa S.H., Poirier M.C. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc. Natl. Acad. Sci. U. S. A. 84:1987;5024-5028.
5. Blommaert F.A., Michael C., Terheggen P.M.A.B., Muggia F.M., Kortes V., Schornagel J.H., Hart A., Den Engelse L. Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method-interindividual variation and correlation with disease response. Cancer Res. 53:1993;5669-5675.
6. Gately D.P., Howell S.B. Cellular accumulation of the anticancer agent cisplatin - A review. Br. J. Cancer. 67:1993;1171-1176.
7. Eastman A., Schulte N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry. 27:1988;4730-4734.
8. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells. 2:1990;275-280.
9. Hickman J.A. Apoptosis induced by anticancer drugs. Cancer Metast. Rev. 11:1992;121-139.
10. De Graeff A., Slebos R.J.C., Rodenhuis S. Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother. Pharmacol. 22:1988;325-332.
11. Richon V.M., Schulte N., Eastman A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum (II) in murine leukemia L1210 cells. Cancer Res. 47:1987;2056-2061.
12. Ohmori T., Morikage T., Sugimoto Y., Fujiwara Y., Kasahara K., Nishio K., Ohta S., Sasaki Y., Takahashi T., Saijo N. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP). Jpn. J. Cancer Res. 84:1993;83-92.
13. Gibbons G.R., Kaufmann W.K., Chaney S.G. Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells. Carcinogenesis. 12:1991;2253-2257.
14. Terheggen P.M.A.B., Floot B.G.J., Lempers E.L., Van Tellingen O., Begg A.C., Den Engelse L. Antibodies against cisplatin-modified DNA and cisplatin modified (di)nucleotides. Cancer Chemother. Pharmacol. 28:1991;185-191.
15. Fichtinger-Schepman A.M.J., Van der Veer J.L., Luiten S.A., Den Hartog H.J., Lohman P.H.M., Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification and quantitation. Biochemistry. 24:1985;707-713.
16. Fichtinger-Schepman A.M.J., Van Oosterom A.T., Lohman P.H.M., Berends F. Cis-diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res. 47:1988;3000-3004.
17. Fichtinger-Schepman A.M.J., Dijt F.J., De Jong W.H., Van Oosterom A.T., Berends F. Nicolini M. Platinum and other Metal Co-ordination Compounds in Cancer Chemotherapy. 1988;32-46 Martinus Nijhoff, Boston.
18. Fichtinger-Schepman A.M.J., Van Dijk-Knijnenburg H.C.M., Dijt F.J., Van der Velde-Visser S.D., Berends F., Baan R.A. Effects of thiourea and ammonium bicarbonate on the formation and stability of bifunctional cisplatin-DNA adducts: consequences for the accurate quantification of adducts in (cellular) DNA. J. Inorg. Biochem. 58:1995;177-191.
19. Gibbons G.R., Page J.D., Chaney S.G. Treatment of DNA with ammonium bicarbonate or thiourea can lead to underestimation of platinum-DNA monoadducts. Cancer Chemother. Pharmacol. 29:1991;112-116.
20. Fichtinger-Schepman A.M.J., Van Dijk-Knijnenburg H.C.M., Van der Velde Visser S.D., Berends F., Baan R.A. Cisplatin- and carboplatin-DNA adducts: is Pt-AG the cytotoxic lesion? Carcinogenesis. 16:1995;2447-2453.
21. Terheggen P.M.A.B., Dijkman R., Begg A.C., Dubbelman R., Floot B.G.J., Hart A.A.M., Den Engelse L. Monitoring of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II) with DNA in cells from platinum-treated cancer patients. Cancer Res. 48:1988;5597-5603.
22. Van Benthem J., Wild C.P., Vermeulen E., Den Engelse L., Scherer E. Immunocytochemical localization of DNA adducts induced by a single dose of N-nitroso-N-methylbenzylamine in target and non-target tissues of tumor formation in the rat. Carcinogenesis. 12:1991;1831-1837.
23. Meijer C., Mulder N.H., Timmer-Bosscha H., Sluiter W.J., Meersma G.J., de Vries E.G.E. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res. 52:1992;6885-6889.
24. Terheggen P.M.A.B., Emondt J.Y., Floot B.G.J., Dijkman R., Schrier P.I., Den Engelse L., Begg A.C. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Cancer Res. 50:1990;3556-3561.
25. den Hartog J.H.J., Altona C., van Boom J.H., van der Marel G.A., Haasnoot C.A.G., Reedijk J. Cis-diamminedichloroplatinum(II) induced distortion in a double-helical DNA fragment. J. Am. Chem. Soc. 106:1984;1528-1530.
26. Leng M. Distortions induced in double-stranded oligonucleotides by the binding of cis- or trans-diammine-dichloroplatinum(II) to the d(GTG) sequence. Nucl. Acids Res. 18:1990;4395-4398.
27. Gibbons G.R., Page J.D., Mauldin S.K., Husain I., Chaney S.G. Role of carrier ligand in platinum resistance in L1210 cells. Cancer Res. 50:1990;6497-6501.
28. Welters M.J.P., Fichtinger-Schepman A.M.J., Baan R.A., Hermsen M.A.J.A., Van der Vijgh W.J.F., Cloos J., Braakhuis B.J.M. Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines. Int. J. Cancer. 71:1997;410-415.
29. Kaufmann W.K. Pathways of human cell post-replication repair. Carcinogenesis. 10:1989;1-11.
30. Bohr V.A. Gene-specific DNA repair. Carcinogenesis. 12:1991;1983-1992.
31. Dijt F.J., Fichtinger-Schepman A.M.J., Berends F., Reedijk J. Formation, repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res. 48:1988;6058-6062.
32. Zhen W.P., Evans M.K., Haggerty C.M., Bohr V.A. Deficient gene-specific repair of cisplatin-induced lesions in xeroderma-pigmentosum and Fanconi anemia cell lines. Carcinogenesis. 14:1993;919-924.
33. Schmidt W., Chaney S.G. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res. 53:1993;799-805.
34. Donahue B.A., Augot M., Bellon S.F., Treiber D.K., Toney J.H., Lippard S.J., Essigmann J.M. Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Biochemistry. 29:1990;5872-5880.
35. Pil P.M., Lippard S.J. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science. 256:1992;234-237.
36. Brown S.J., Kellett P.J., Lippard S.J. Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science. 261:1993;603-605.
37. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.